Clinical trial · Interventional
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
NCT01187303CI-TRIAL-00019675completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed NLPHL | Nodular Lymphocyte Predominant B-Cell Lymphoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ofatumumab | Drug | Ofatumumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall response rate
- timeFrame
- 12 months after end of treatment
Secondary outcomes (3)
- measure
- duration of response
- timeFrame
- 12 months after end of treatment
- measure
- Progression free survival
- timeFrame
- 12 months after end of treatment
- measure
- adverse events
- timeFrame
- 12 months after end of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * relapsed nodular lymphocyte predominant hodgkin lymphoma * age 18 - 75 * review of diagnosis by experienced pathologist * no major organ dysfunction Exclusion Criteria: * classical hodgkin lymphoma * CD20 antibody treatment within the last 6 months prior enrollment * chronic or current infectious disease requirering systemic antibiotics * other past or current malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.